[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354549-105":59,"doc-detail-354549-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","landscape-of-t-cell-bispecific-antibodies-in-cancer-therapy-therapeutic-strategies-challenges-and-future-prospection","Landscape of T-cell Bispecific Antibodies in Cancer Therapy - Therapeutic Strategies, Challenges and Future Prospection","","T-cell bispecific antibodies (TCBs), a subclass of bispecific antibodies, are engineered to bind two distinct antigens (or two epitopes on one antigen) and simultaneously redirect T cells toward tumor cells. By engaging TCR-mediated signaling and reshaping immune checkpoint pathways, TCBs strengthen antitumor immunity and have shown meaningful efficacy, especially in hematologic cancers. Despite promise, adoption is limited by immune-related toxicities such as CRS and ICANS, plus resistance driven by the tumor microenvironment. This review compares platforms, mechanisms, and clinical outcomes while outlining translational bottlenecks and emerging solutions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/landscape-of-t-cell-bispecific-antibodies-in-cancer-therapy-therapeutic-strategies-challenges-and-future-prospection/354549/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/landscape-of-t-cell-bispecific-antibodies-in-cancer-therapy-therapeutic-strategies-challenges-and-future-prospection/354549.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do T-cell bispecific antibodies redirect immune killing against tumors?","Question",{"text":112,"@type":113},"TCBs bind two antigens (or two epitopes on one antigen) to simultaneously engage T cells and tumor cells. This redirects cytotoxic T lymphocytes to eliminate malignant cells through TCR-mediated signaling and immune checkpoint pathway modulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major safety and efficacy challenges limit clinical adoption of TCBs?",{"text":117,"@type":113},"Clinical adoption is impeded by severe immune-related toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). In addition, resistance can arise from the immunosuppressive tumor microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review cover to address translational hurdles for TCB therapies?",{"text":121,"@type":113},"The review analyzes TCB molecular design, mechanisms of action, and clinical performance across indications. It compares current TCB platforms and evaluates translational bottlenecks, including emerging strategies such as novel antibody formats, rational combination regimens, AI-driven antibody design, and antibody-drug conjugates (ADCs).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354549,1790176270,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Jiao et al. Molecular Cancer (2026) 25:189 Molecular Cancer  \n[https://doi.org/10.1186/s12943-026-02685-8](https://doi.org/10.1186/s12943-026-02685-8)  \nREVIEW Open Access  \nLandscape ofT-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection  \nGuanda Jiao1, Hongsen Peng1, Yiqi Yang1, Yang Liu1, Xiaoxi Liu1, Yuanjia Hu4, Yeneng Dai1,2*, Zhoufang Li3* and Qi Zhao1,2*  \nAbstract  \nT-cell bispecific antibodies (TCBs), a specialized subclass of bispecific antibodies (BsAbs), are engineered to simultaneously engage T cells and tumor cells by binding two distinct antigens—or two epitopes on a single antigen—thereby redirecting cytotoxic T lymphocytes to eliminate malignant cells. These agents enhance anti-tumor immunity through dual mechanisms: direct activation ofT cell receptor (TCR)-mediated signaling and modulation ofT cell function via immune checkpoint (ICP) pathways. Clinically, TCBs have demonstrated transformative efficacy, particularly in hematologic cancers, heralding a new era in tumor immunotherapy.  \nDespite their therapeutic promise, widespread clinical adoption ofTCBs is impeded by significant challenges—including severe immune-related toxicities such as cytokine release syndrome (CRS) and immune effector cellassociated neurotoxicity syndrome (ICANS), as well as resistance conferred by the immunosuppressive tumor microenvironment (TME) . This review provides a comprehensive analysis ofTCBs, encompassing their molecular design, mechanisms of action, and clinical performance across oncology indications. We systematically compare current TCB platforms with respect to therapeutic strategy, structural format selection, safety profiles, and clinical outcomes. Additionally, we critically evaluate the major translational hurdles facing TCB-based therapies and explore emerging solutions—including the development of novel format antibodies, rational combination regimens with immune checkpoint inhibitors or other immunomodulators, the application of artificial intelligence (AI) in de novo antibody design, and antibody drug conjugates (ADCs) . In summary, this review not only highlights the current landscape and limitations ofTCBs but also outlines actionable strategies to overcome existing barriers—serving as a valuable resource for researchers, clinicians, and biopharmaceutical developers striving to advance the next generation of T-cell redirecting therapies into clinical practice.  \nKeywords Bispecific antibody, Cancer therapy, T cell, Immune checkpount  \n*Correspondence: Yeneng Dai [yenengdai@um.edu. mo](yenengdai@um.edu. mo)[ ](yenengdai@um.edu. mo)Zhoufang Li[lizf@sustech.edu.cn](lizf@sustech.edu.cn)[ ](lizf@sustech.edu.cn)Qi Zhao [qizhao@um.edu. mo](qizhao@um.edu. mo)  \n1Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, SAR 999078, China  \n2MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau 999078, China  \n3SUSTech Core Research Facilities, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China  \n4State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, SAR, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article","cbCaie2yz3guGLGY","https://ap.wps.com/l/cbCaie2yz3guGLGY","pdf",1983015,22,"English","# Introduction\n## T-cell roles in adaptive immunity and antitumor therapy\n## Immune checkpoints and tumor immune evasion","[{\"question\":\"How do T-cell bispecific antibodies redirect immune killing against tumors?\",\"answer\":\"TCBs bind two antigens (or two epitopes on one antigen) to simultaneously engage T cells and tumor cells. This redirects cytotoxic T lymphocytes to eliminate malignant cells through TCR-mediated signaling and immune checkpoint pathway modulation.\"},{\"question\":\"What major safety and efficacy challenges limit clinical adoption of TCBs?\",\"answer\":\"Clinical adoption is impeded by severe immune-related toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). In addition, resistance can arise from the immunosuppressive tumor microenvironment.\"},{\"question\":\"What does the review cover to address translational hurdles for TCB therapies?\",\"answer\":\"The review analyzes TCB molecular design, mechanisms of action, and clinical performance across indications. It compares current TCB platforms and evaluates translational bottlenecks, including emerging strategies such as novel antibody formats, rational combination regimens, AI-driven antibody design, and antibody-drug conjugates (ADCs).\"}]","Landscape of T-cell Bispecific Antibodies in Cancer Therapy - Therapeutic Strategies, Challenges and Future Prospection | PDF",1790111853,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da26876fbd92ce96de5e39004fdfd0dc.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a4c5eaa8f533cc485c6167ae2e7e1fd.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5804854e9275327ab855c6eced06265.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/555d854f664018888e8fed49e1826610.webp",980,1306]